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Superior Vena Cava Defibrillator Coils Make
Transvenous Lead Extraction More Challenging and RiskierTo the Editor: Studies have demonstrated equivalent defibrillation
efficacy and all-cause mortality in patients with single and dual coil
implantable cardioverter-defibrillator (ICD) leads (1,2). Despite
this equivalency, the vast majority of implanted ICD leads are dual
coil (3). The widespread use of dual coil ICD leads is relevant to
lead management because of the challenges and risks of trans-
venous lead extraction (TLE). Defibrillator coils enable fibrous
tissue in-growth and the superior vena cava (SVC) coil is often
positioned in a high-risk region and may be associated with
increased difficulty and risk of TLE. The purpose of this analysis
was to determine the relationship between the presence of an SVC
coil and the risk of major complications and the difficulty of TLE.
A retrospective analysis of patient and lead characteristics,
procedural outcomes, and complications of consecutive patients
undergoing ICD lead extraction at 9 high-volume centers was
performed. The TLE technique has been described previously (4).
Extraction time was defined as the active time for successful
removal of all targeted leads from the first attempt to remove the
lead to final lead removal. Difficulty of TLE was defined as the
combined endpoint of the need for specialized extraction tools,
namely, powered sheaths, and/or extraction time75th percentile.
Outcomes were based on the Heart Rhythm Society lead
management consensus (5). Patients were followed up in-hospital,
and intraprocedural outcomes are reported. Continuous variables
were expressed as mean  SD or median and interquartile range.
Fisher exact tests were used to compare categorical variables with
the exception of the complications data. Given the occurrence of
zero cell data with major complications in single coil ICD leads,
Baseline and Procedural CharacteristicsTable 1 Baseline and Procedural Characteristics
Characteristics Single Coil (
Baseline characteristics
Age, yrs 59
Male 70.9 (273
TLE indication
Systemic infection 24.1 (92)
Local infection 33.3 (127
Lead malfunction 23.8 (91)
Device upgrade 15.7 (60)
Other 12 (3.1)
Implant duration, months 48.3 (24.1
No. of leads explanted 1.5 (1–2)
Active fixation mechanism 81.9 (266
ePTFE/MABF leads 62.5 (198
Procedural characteristics
Procedure time, min 4.5 (2–22
ES assistance 67.4
Powered sheath use 43.3
Complete procedural success 99.0
Major complications 0%Values are mean  SD, % (n), or median (interquartile range). ePTFE  expand
cardioverter-defibrillator; IQR  interquartile range; MABF medical adhesive bthe likelihood ratio test was used. Logistic regression analysis was
utilized to identify clinical variables associated with the combined
endpoint. All tests of significance were 2-sided, with p value 
0.05 considered significant. Statistical data analysis was performed
using SAS Version 9.2 (SAS Institute, Cary, North Carolina).
Between January 2000 and February 2011, a total of 2,201
patients underwent TLE of 2,274 ICD leads. Lead model infor-
mation was not available in 25 cases, and these patients were
excluded from further analysis. Baseline and procedural character-
istics and outcomes are presented in Table 1. The majority of ICD
leads removed had an SVC coil (82.4%) and an active fixation
mechanism (73.0%). Extraction sheath assistance was imple-
mented in 73% cases, with powered sheath use necessary in 55% of
cases. Complete procedural success was achieved in 98.8% of cases.
There was no difference in procedural time, extraction sheath use,
or procedural success between single and dual coil leads. Powered
sheath use was more common with dual coil leads (p  0.0001).
Eighteen major complications were observed, all in cases in-
volving dual coil ICD leads (p  0.031). No single lead model
predominated in the cases with complications. These included 10
cases of pericardial tamponade and 1 case each of respiratory failure
and hemodynamic instability requiring vasopressors/intra-aortic
balloon pump placement. Four cases of pericardial tamponade
required urgent/emergent thoracotomy/sternotomy for treatment.
In these, the sites of tears/avulsions were identified as an SVC tear,
an avulsion in the right atrium, and 2 cases of tears at the RA/SVC
junction. The sites of tear/avulsion in the cases of pericardial
tamponade managed with percutaneous drainage were presumed
85) Dual Coil (n  1,791) p Value
62 15
63.0 (1,373)
34.6 (618)
41.6 (744)
11.3 (201)
5.3 (95)
128 (7.2)
) 38.2 (19.5–60.6)
1 (1–2)
71.1 (1,066)
47.9 (728)
7 (3–43.8) 0.002
74.6% 0.005
57.3% 0.0001
98.7% NS
1.0% 0.031n  3
17
)
)
–72.1
)
)
)
%
%
%ed polytetrafluoroethylene; ES  extraction sheath; ICD  implantable
ack-filled; NS  not significant; TLE  transvenous lead extraction.
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location of the tear/avulsion in the remaining 3 percutaneous
pericardial drainage cases. One patient subsequently died after
emergent sternotomy, and 6 additional deaths were observed
(0.31%, related to device-related systemic infection in all cases).
The deaths occurred between post-operative day 1 and post-
operative day 19. All patients had a pre-operative diagnosis of
Staphylococcal bacteremia/endocarditis.
Difficulty of TLE was significantly associated with the presence
of an SVC coil on both unadjusted analysis (1.73 [1.38 to 2.15],
p  0.0001) and after adjusting for age, sex, implant duration,
TLE indication, fixation mechanism, number of leads removed,
and presence of expanded polytetrafluoroethylene-coated/medical
adhesive back-filled ICD coils (2.57 [1.95 to 3.38], p  0.0001).
This is the first study to report the risk of complications and
difficulty associated specifically with the extraction of dual coil
ICD leads. Our group of high-volume, experienced operators
found TLE of ICD leads with an SVC coil to be associated with
a 1.0% major complication rate as compared with no major
complications during removal of single coil ICD leads despite
longer lead implant durations among the single coil leads (p 
0.008). In addition, dual coil ICD leads were 2.6 times more
difficult to remove after adjusting for age, sex, implant duration,
TLE indication, presence of expanded polytetrafluoroethylene-
coated/medical adhesive back-filled ICD coils, fixation mecha-
nism, and number of leads removed (p  0.0001).
Dual coil ICD leads appear to have become the de facto choice
for device implantation. The preferred use of dual coil ICD leads
seems to be a vestige of the abdominal device era when the
presence of a second high voltage shocking coil was necessary.
Despite the advent of pectoral, active cans and biphasic defibril-
lation waveforms, dual coil ICD leads remain the considered
standard on the basis of habit and early small studies demonstrat-
ing superior defibrillation efficacy. Recent and more contemporary
studies contradict these findings (1,2).
The challenges and risks of TLE are directly related to the
robust fibrosis that develops in areas of direct contact between the
lead and the vasculature and endocardium. The ICD defibrillator
coils enable vigorous fibrous tissue in-growth resulting in dense
vascular and myocardial adhesions, adding to the challenge of
extraction. An SVC coil, in an area at high risk, exacerbates this
problem.
Although fibrotic tissue ingrowth into the SVC coil is the
postulated mechanism for the observed findings in this study, lead
design and diameter and the location of the SVC coil may also play
a role. Many experts consider the presence of an SVC coil to increase
the challenge and risk of extraction, but this is the first study to
directly compare extraction of single and dual coil ICD leads.
Given the defibrillation equivalency of single and dual coil leads,
these findings suggest that a paradigm shift is warranted. In the
current era, lead management should predominate and implanters
should “think before they choose” and opt for single coil defibril-
lator leads as the new standard of care.
This study is a retrospective analysis, and thus is subject to bias
and the other well-known limitations of nonexperimental designs.
The cohort was limited to 9, high-volume centers. This selection
of highly experienced sites may have led to an under-estimation of
the “real world” complication rate.
In conclusion, the presence of an SVC coil is associated with
significantly higher complication rates and TLE of dual coil ICD
leads is 2.6 times more difficult as compared with single coil ICDleads. Given the lack of benefit of dual coil ICD leads in the vast
majority of patients and the above noted risks, routine implanta-
tion of dual coil ICD leads should be discouraged.
Laurence M. Epstein, MD†
Charles J. Love, MD‡
Bruce L. Wilkoff, MD§
Mina K. Chung, MD§
Joseph W. Hackler, DO§
Maria Grazia Bongiorni, MD
Luca Segreti, MD
Roger G. Carrillo, MD¶
Pablo Baltodano, MD¶
Avi Fischer, MD#
Charles Kennergren, MD, PhD**
Roger Viklund**
Suneet Mittal, MD††
Aysha Arshad, MD††
Kenneth A. Ellenbogen, MD‡‡
Roy M. John, MD, PhD†
*Melanie Maytin, MD†
*Brigham and Women’s Hospital
75 Francis Street
Boston, Massachusetts 02115
E-mail: mmaytin@partners.org.
http://dx.doi.org/10.1016/j.jacc.2012.12.014
From the †Brigham and Women’s Hospital, Boston, Massa-
chusetts; ‡Ohio State University Medical Center, Columbus,
Ohio; §Cleveland Clinic Lerner College of Medicine, Case
Western Reserve University School of Medicine, Cleveland, Ohio;
University Hospital, Pisa, Italy; ¶University of Miami Miller
School of Medicine, Miami, Florida; #Mount Sinai School of
Medicine, New York, New York; **Sahlgrenska University
Hospital, Göteborg, Sweden; ††The Valley Health System and
Columbia University College of Physicians and Surgeons, New
York, New York; and the ‡‡Medical College of Virginia/VCU
School of Medicine, Richmond, Virginia.
Please note: Dr. Epstein has received research grants from and is a consultant for
Boston Scientific, Medtronic, Spectranetics, and St. Jude Medical, and has equity in
and served as a board member for Carrot Medical. Dr. Love has received research
grants from Biotronik, Boston Scientific, Medtronic, and St. Jude Medical, and is a
consultant for Biotronik, Boston Scientific, Cook Vascular, Medtronic, Sorin/ELA,
St. Jude Medical, Spectranetics, and TyRx. Dr. Wilkoff has received research grants
from Biotronik, Boston Scientific, LifeWatch, Medtronic, Spectranetics, and St. Jude
Medical, and is a consultant for Boston Scientific, LifeWatch, Medtronic, Spectra-
netics, and St. Jude Medical. Dr. Chung participates in industry-sponsored research
with Biotronik, Boston Scientific, Medtronic, and St. Jude Medical, and serves on a
steering committee for Biotronik. Dr. Fischer is currently a paid employee of St. Jude
Medical. Dr. Carrillo is a consultant for Medtronic, Sorin/ELA, Spectranetics, and
St. Jude Medical. Dr. Kennergren has consulted with, presented on behalf of, or
performed studies with Biotronik, Boston Scientific, Medtronic/Vitatron, Mentice,
Sorin/ELA, Spectranetics, and St. Jude Medical. Roger Viklund is currently a paid
employee of Boston Scientific. Dr. Mittal has received fellowship and research
support from and is a consultant for Bard, Biosense Webster, Biotronik, Boehringer,
Boston Scientific, Medtronic, Spectranetics, and St. Jude Medical. Dr. Ellenbogen
has received research grants from and is a consultant for Boston Scientific and
Medtronic, and has received honorarium from Biotronik, Boston Scientific,
Medtronic, and St. Jude Medical. Dr. John participates in industry-sponsored
research with Biosense Webster, Medtronic, and Thermedical Inc., and is a
consultant for St. Jude Medical. All other authors have reported they have no
relationships relevant to the contents of this paper to disclose.
R989JACC Vol. 61, No. 9, 2013 Correspondence
March 5, 2013:985–91REFERENCES
1. Aoukar PS, Poole JE, Johnson GW, et al. No benefit of a dual coil over
a single coil ICD lead: evidence from SCD-HEFT. Circulation
2010;122:A13672.
2. Mokabberi R, Haftbaradaran A, Pranesh S, et al. Defibrillation thresh-
olds in single versus dual coil ICD lead systems: is there any difference?
Circulation 2011;124:A17919.
3. Neuzner J, Carlsson J. Dual- versus single-coil implantable defibrillator
leads: review of the literature. Clin Res Cardiol 2012;101:239–45.
4. Maytin M, Love CJ, Fischer A, et al. Multicenter experience with
extraction of the Sprint Fidelis implantable cardioverter-defibrillator
lead. J Am Coll Cardiol 2010;56:646–50.
5. Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart
Rhythm Society expert consensus on facilities, training, indications, and
patient management. Heart Rhythm 2009;6:1085–104.
Letters to the Editor
Is Prolong Use of Statins
Associated With Increase
in the Risk of Diabetes?
The study by Wang et al. (1) assessed the risk of diabetes
associated with statin use in the general population. The authors
concluded that statin therapy is associated with an elevated risk for
diabetes. However, the study does not indicate the classes or
proportion of the different antihypertensive drugs (AHDs) admin-
istered in the statin-treated and control populations. This infor-
mation is imperative because thiazide diuretics and specific beta-
blockers exhibit undesirable glycemic effects.
Assessment of the ALLHAT study (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial) re-
vealed that the 4-year incidence of new-onset diabetes mellitus was
significantly elevated in the chlorthalidone group compared with
either the amlodipine or lisinopril group (11.6% vs. 9.8% and 8.1%,
respectively; p  0.05) (2). Comparable outcomes were also
obtained from the INSIGHT (International Nifedipine GITS
Study of Intervention as a Goal in Hypertension Treatment) and
ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm) trials (3,4). These effects of diuretic
AHDs on glucose metabolism are plausibly due to hypokalemia
induced by these drugs.
Hyperglycemia induced by beta-blockers is due to the reduction
in peripheral blood flow, followed by the channeling of blood away
from locales of glucose uptake, thereby reducing glucose clearance.
A systematic review by Elliott and Meyer (5), with 48 randomized
groups of 22 clinical trials involving 143,153 participants, revealed
that association of AHDs with incident diabetes is the highest for
beta-blockers and diuretics (in rank order).
Therefore, the question that remains unrequited in the current
study – “Is the adverse glycemic effect of statins observed in the
present study getting augmented, as a greater number of subjects in
the statin-group are being treated for hypertension with diuretics
or beta-blockers?”
Furthermore, a prospective population-based cohort study by
Dunder et al. (6) examined the impact of blood glucose elevationon the risk of developing myocardial infarction in individuals
between 50 and 60 years of age who were receiving AHDs. They
found that the elevated blood glucose and proinsulin levels
produced by use of diuretics and beta-blockers were linked to the
increased risk of myocardial infarction in these subjects. Therefore,
in the current study, if the statin-treated group has a higher
number of subjects receiving diuretics and beta-blockers, then the
favorable outcome of statins may be further augmented.
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Reply
We thank Dr. Banerjee for his comments regarding our publica-
tion on statin therapy and the risk of incident diabetes (1). He
highlighted for us the importance of diabetogenic effects of
concomitant medications, particularly diuretics and beta-blockers,
which have been independently associated with a higher risk of
diabetes (2,3).
The effects of diuretics and beta-blockers were essential in our
analysis because 73.9% of subjects in our population had hyper-
tension and 8.6% had heart failure. Our approach of matching
measurable comorbid risks to establish the study cohort resulted in
a similar distribution of demographic characteristics and cardio-
vascular comorbidities. There was no significant difference in the
proportions of diuretic and beta-blocker use among the control
group and the statin group (13.1% vs. 13.0%, p  0.795 [diuret-
ics]; 34.5% vs. 34.3%, p  0.693 [beta-blockers]). Statins, diuret-
ics, and beta-blockers were associated with an increase in risk of
incident diabetes; hazard ratios (95% confidence intervals) were
